Engflag

Glycinorm-80

Quick links to important sections

Glycinorm-80

Glycinorm-80_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glycinorm-80

Quick Facts

  • Active Ingredient: Gliclazide
  • Drug Class: Sulfonylureas (Insulin Secretagogues)
  • Primary Use: Management of Type 2 Diabetes Mellitus

Glycinorm-80 is an oral prescription medication used to help manage Type 2 Diabetes Mellitus in adults when diet, exercise, and weight reduction alone are insufficient to maintain blood glucose control. It contains gliclazide, an active ingredient that belongs to the class of antidiabetic drugs known as sulfonylureas.

Mechanism of Action

Glycinorm-80 works primarily by stimulating the release of insulin from the beta cells in the pancreas. As a sulfonylurea, gliclazide achieves this effect by binding to specific receptors (SUR1) on the beta cells, which in turn leads to the closure of ATP-sensitive potassium channels. This action causes the cell membrane to depolarize, opening voltage-dependent calcium channels, and ultimately triggering the release of stored insulin into the bloodstream.

By increasing insulin levels, the medication facilitates the uptake of glucose by the body's tissues, thereby lowering the elevated blood sugar levels characteristic of Type 2 diabetes. Controlling blood sugar is essential for reducing the long-term risk of serious diabetes-related complications, such as nerve damage (neuropathy), kidney damage (nephropathy), and vision problems (retinopathy).

What side effects are possible with Glycinorm-80?

Possible Side Effects and Safety Information

The safety profile of Glycinorm-80, which contains gliclazide, is characterized primarily by adverse reactions classified according to their frequency in regulatory documentation.

The most prominent and common adverse reaction documented is hypoglycemia (low blood sugar), which is related to the drug's mechanism of stimulating insulin release. Other documented effects are categorized across several System-Organ Classes.

Adverse Reaction Categories

Classification Examples of Documented Effects
Common Hypoglycemia (low blood sugar)
Uncommon Gastrointestinal disturbances (e.g., nausea, vomiting, constipation)
Rare Hematological disorders (e.g., leukopenia, agranulocytosis), Hepatic disorders (e.g., jaundice, hepatitis)

Serious Adverse Reactions and Safety Constraints

While rare, the official safety profile notes the potential for serious adverse reactions, including severe hypoglycemia, hepatitis, and certain severe blood disorders like agranulocytosis.

Safety notes also indicate that the risk of hypoglycemia is a particular concern in specific populations. The medication is formally contraindicated for use in individuals with severe hepatic failure or severe renal failure due to the significantly increased risk of severe hypoglycemia. Furthermore, transient visual disturbances may occur early in treatment, often coinciding with initial changes in blood glucose levels.

Overdose and Emergency Response

The regulatory documentation states that an overdose of Glycinorm-80 (Gliclazide) leads to profound and prolonged hypoglycaemia (severely low blood sugar), which is the central documented clinical event. This primary manifestation triggers a recognizable cascade of neurological and systemic signs. Initial documented symptoms include sweating, intense hunger, anxiety, tremor, confusion, dizziness, and fast heartbeat. This state can progress to severe neurological complications, including convulsions and eventual coma, posing a risk of permanent neurological damage.

The official labeling mandates immediate medical attention for any severe or prolonged episode of low blood sugar. If the patient is found to be unconscious, emergency services must be called immediately. For mild symptoms, initial management involves taking oral carbohydrates. Severe cases require hospitalisation and intravenous glucose administration. Due to the risk of recurrent low blood sugar, close monitoring for a minimum of 12 to 24 hours is typically required. Regulatory information also notes that elderly subjects and patients with severe hepatic or renal insufficiency are particularly vulnerable to these severe reactions.

Therapeutic Uses of Glycinorm-80

What Glycinorm-80 Treats: Main Uses and Benefits

Glycinorm-80 is commonly used to help manage the metabolic condition of Type 2 Diabetes Mellitus in adults, primarily targeting chronic hyperglycemia (high blood sugar levels). This therapeutic application is necessary when dietary measures, physical exercise, and weight loss alone are not sufficient to control blood glucose. The drug is commonly used to help with managing blood glucose and HbA1c levels.

Therapeutic Benefit and Symptom Relief

The medication addresses symptom clusters that may create noticeable physiological strain, specifically symptoms related to systemic imbalance such as excessive thirst, frequent urination, and generalized fatigue. This provides supportive relief that helps patients cope more steadily with these difficult episodes. The support of sustained glucose management contributes to easing the overall symptom load and may assist with reducing the probability of long-term diabetes-related complications.

“Effective glucose management is commonly used across conditions presenting with episodic or fluctuating symptom patterns.”

Quick Fact: Relief for Symptoms of Hyperglycemia

The medication assists in easing symptoms that interfere with daily functioning, applied across domains where additional symptomatic support is needed.

Eligibility and Restrictions for Use

Who Can and Cannot Use Glycinorm-80?

Eligibility for Glycinorm-80 (Gliclazide) is strictly defined by regulatory authorities and the medication is only approved for specific patient populations.

Approved and Restricted Populations

Population Group Eligibility Status
Adults Approved for managing Type 2 Diabetes Mellitus
Older Adults (Aged 65 years) Approved, but requires caution and monitoring
Children and Adolescents Not Recommended (Safety and efficacy not established)

Absolute Contraindications (Must Not Use)

The medicine is officially contraindicated and must not be used by patients with the following conditions or characteristics:

  • Type 1 Diabetes Mellitus or severe, uncontrolled diabetes such as Diabetic Ketoacidosis.
  • Severe Hepatic (liver) or Renal (kidney) Impairment.
  • Known Hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.
  • Pregnancy or Breastfeeding (Insulin is the standard of care in these cases).
  • Acute physiological Stress Conditions like severe trauma, surgery, or serious infection.

Use is also prohibited in patients with rare hereditary metabolic disorders like galactose intolerance, due to tablet excipients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interaction patterns for gliclazide (the active ingredient in Glycinorm-80) as published in government regulatory documents.

Formal Contraindication and High-Risk Combinations

Co-administration with Miconazole (systemic or oromucosal gel) is formally contraindicated due to the risk of severe potentiation of the glucose-lowering effect. Combinations with systemic Phenylbutazone and Danazol are not recommended by regulatory authorities.

Interactions Affecting Blood Glucose Levels

Interactions are generally classified based on their effect on blood glucose control:

  • Increased Risk of Hypoglycemia (Potentiation): Co-administration with other Antidiabetic Agents, ACE Inhibitors (e.g., captopril), Beta-blockers, MAOIs, Clarithromycin, and Fluconazole may potentiate gliclazide's action. These are documented as pharmacodynamic effects that increase the risk of low blood sugar.

  • Increased Risk of Hyperglycemia (Reduced Efficacy): Agents such as Glucocorticoids (systemic and local), Danazol, and Ritodrine, Salbutamol, or Terbutaline (I.V. route) are documented to reduce the therapeutic efficacy of gliclazide.

Pharmacokinetic and Substance Interactions

Co-use with preparations containing St John's Wort is documented to reduce gliclazide exposure ( AUC and C max), a pharmacokinetic effect that can reduce blood sugar control. Consumption of Alcohol is not recommended as it increases the hypoglycemic reaction by inhibiting the body's compensatory mechanisms. Regarding population-specific notes, dysglycemia with fluoroquinolones is specifically noted as a concern for elderly patients.

Mechanism of Action

How Glycinorm-80 Works: Mechanism of Action

Glycinorm-80, which contains Gliclazide, exerts its primary action by targeting the ATP-sensitive potassium ( K ATP) channels in the pancreatic beta-cells. The drug functions as an inhibitor, binding specifically to the Sulfonylurea Receptor 1 ( SUR1) subunit of the channel complex.

This binding closes the K ATP channels, preventing potassium ion efflux and causing the beta-cell membrane to depolarize. This cellular event triggers the opening of voltage-gated calcium ( Ca^2+) channels, allowing Ca^2+ ions to rapidly flow into the cytoplasm. This influx of Ca^2+ acts as the final intracellular signal, forcing the exocytosis of insulin from its storage granules and resulting in an increase in circulating insulin.

The released insulin facilitates glucose uptake by peripheral tissues and suppresses hepatic glucose production. Furthermore, the drug's mechanism also engages domains that modulate blood vessel function and platelet activity, modulating pathways associated with microvascular processes.

Dosage and Administration Information

How to Use Glycinorm-80

This section describes the high-level, standardized usage of Glycinorm-80 (gliclazide 80 mg immediate-release tablet). The administration guidelines establish the approved routes, dosing ranges, and mandatory procedural conditions for use.

Official Administration Guidelines

Instruction Detail
Route of Administration The medication is for oral use only.
Dosing Schedule The typical initial total daily dose ranges from 40 mg to 80 mg. The usual maintenance dose is between 80 mg and 160 mg daily, with a maximum daily limit of 320 mg.
Timing with Meals The tablet must be taken with a meal, primarily at breakfast time, to align with meal-induced glucose surges.
Preparation The tablet is scored and may be divided to achieve a 40 mg dose. It must be swallowed whole with water and must not be chewed.
Frequency Doses up to 160 mg may be taken once daily. Doses exceeding 160 mg must be administered in divided doses throughout the day.
Dose Titration Dose adjustments should proceed gradually, with a minimum interval of at least several days or up to one month between increments, informed by the patient's metabolic response.
Missed Dose If a dose is forgotten, it is skipped. The following day's dose should not be increased to compensate.

Population-Specific Use

For older adults and patients with mild to moderate renal impairment, the same established dosing regimen may be used, though careful monitoring is stipulated. Use in the pediatric population has not been officially established and is not recommended.

The entire usage protocol is designed for the long-term, chronic management of the condition, adhering to standardized limits and procedures.

Recent Clinical Evidence

Overview of Clinical Research

Glycinorm-80 contains the active substance gliclazide, which is classified as a second-generation sulfonylurea agent. Research focuses on its role in managing blood glucose levels in adults diagnosed with Type 2 diabetes mellitus, particularly when blood sugar control is not achieved through diet and exercise alone.

Studies have consistently evaluated the agent's effect on glycated hemoglobin (HbA1c), which serves as a measure of long-term blood glucose control. Clinical trials have found that use of gliclazide is associated with a reduction in HbA1c levels, which is a primary endpoint for diabetes management.

Safety and Tolerability Profiles

Adverse event data collected from clinical trials indicate that the most commonly reported side effect is hypoglycemia (low blood glucose). This is a known class effect of sulfonylureas. Other frequently reported effects include gastrointestinal disturbances such as nausea, diarrhea, and stomach pain.

Specialized studies have evaluated the drug's use in specific populations, including:

Population Group Research Focus
Elderly Patients Investigated the influence of age on drug clearance and potential for adverse events.
Organ Impairment Studies conducted in patients with kidney or liver impairment evaluated pharmacokinetics and related risk.

Comparative trials have also been conducted, examining the agent against other oral glucose-lowering medications regarding efficacy and the incidence of adverse events over extended periods. Research continues to evaluate the agent across longer durations to further understand its profile.

Frequently Asked Questions (FAQ)

Common questions about Glycinorm-80 (FAQ)

Q: What does the "80" in Glycinorm-80 refer to?

A: The number “80” in Glycinorm-80 indicates the strength of the medicine. This means each immediate-release tablet contains 80 milligrams (mg) of the active ingredient, gliclazide. This composition is consistent with the details provided in official product documents.

Q: Is weight gain a typical side effect associated with Glycinorm-80?

A: Official information indicates that increased weight has been reported as an undesirable effect of this medication. This is consistent with the known class effects of sulfonylurea medicines, to which gliclazide belongs. Information about weight changes is described within the full adverse effects list in the official prescribing documents.

Q: How quickly does Glycinorm-80 begin to have a noticeable effect on blood sugar?

A: Regulatory pharmacokinetic data provides insight into the drug’s activity in the body. The concentration of the active ingredient in the bloodstream typically reaches its maximum level between 2 and 6 hours after the tablet is taken. This peak level provides an indication of when the drug is most active in lowering blood sugar.

Q: Is Glycinorm-80 ever used for conditions other than diabetes?

A: According to official regulatory documents, this medication is only indicated for the management of Type 2 Diabetes Mellitus in adults. It is not approved for use in any other medical conditions listed in the therapeutic indications section.

Q: Do regulatory documents describe any effects of Glycinorm-80 on cholesterol or lipid levels?

A: Official research has primarily focused on the medication's effect on blood glucose. However, regulatory-related studies have suggested that gliclazide may have functional effects that include modulating pathways associated with microvascular processes. Some of this research has also explored a potential influence on plasma lipid levels.

Q: Is Glycinorm-80 associated with an increased risk of specific long-term health issues?

A: The medication is authorized for the long-term, chronic management of Type 2 diabetes. Regulatory processes continually evaluate the drug’s long-term safety, including its profile regarding cardiovascular outcomes. The importance of adherence to the prescribed monitoring schedule for long-term use is noted in usage protocols.

Q: Are there specific foods or drinks that must be avoided while taking Glycinorm-80?

A: Usage conditions note the importance of taking the tablet with a meal, such as breakfast, and maintaining a regular carbohydrate intake. The consumption of alcohol is not advisable with this medication, as it can increase the glucose-lowering effect of gliclazide and raise the risk of low blood sugar.

Q: Can Glycinorm-80 be taken alongside common over-the-counter pain relievers?

A: Official interaction information indicates that certain pain relievers, specifically non-steroidal anti-inflammatory agents (NSAIDs), may increase the glucose-lowering effect of gliclazide. This combination may therefore increase the risk of low blood sugar. This interaction concern applies to both prescription and some over-the-counter NSAIDs.

Q: Does Glycinorm-80 interact with common vitamins or herbal supplements?

A: Regulatory documents specifically describe an interaction with the herbal supplement St John's Wort. The co-use of this supplement is documented to decrease the amount of gliclazide in the body (gliclazide exposure). This reduction can potentially lead to a loss of blood sugar control and elevated glucose levels.

Q: Is Glycinorm-80 available in an extended-release (MR/XL) formulation?

A: Yes, the active ingredient in Glycinorm-80, which is gliclazide, is manufactured in different tablet types. While Glycinorm-80 itself is an immediate-release tablet, the drug substance is also available in modified-release (MR) formulations.

Q: Is there a risk of developing a rash or skin reaction from Glycinorm-80?

A: Official safety profiles classify some skin reactions as rare side effects. These may include skin and subcutaneous tissue disorders such as a rash, itching (pruritus), or hives (urticaria). In extremely rare cases, severe bullous (blistering) reactions have been documented.

Q: Does Glycinorm-80 require special monitoring beyond standard blood sugar checks?

A: While checking blood glucose is the primary type of monitoring, the medication is associated with rare changes in blood counts and raised liver enzyme levels. These changes are typically reversible once the medication is stopped. The need for any additional blood tests is generally determined by the prescribing health professional based on the individual’s profile.

Q: Is it possible to take Glycinorm-80 and insulin at the same time?

A: Yes, official product information confirms that gliclazide can be given as a combination treatment with insulin. This combination is typically considered when control cannot be achieved with gliclazide alone. When used together, this combination requires close medical supervision.

Q: Why is Glycinorm-80 often prescribed with other diabetes medicines?

A: Glycinorm-80 is commonly prescribed as part of a combination treatment to improve blood glucose control. The primary goal of combining it with other anti-diabetic agents, such as biguanides, is to achieve and sustain adequate sugar regulation when a single drug is not sufficient. This approach uses drugs with complementary mechanisms of action.

Q: Can Glycinorm-80 affect blood tests other than blood sugar?

A: Yes, in rare instances, official safety documents describe the possibility of changes in blood counts (hematology) or elevated liver enzyme levels. These potential changes are measured by various blood tests, and they are typically reversible upon discontinuation of the medication.

Q: Is Glycinorm-80 generally considered to be a first-line treatment option?

A: Official therapeutic indications state that the medication is approved for adults with Type 2 diabetes when diet, physical exercise, and weight loss alone are not sufficient. This description places its use after initial lifestyle changes have been attempted, or as an add-on therapy, rather than necessarily the initial first step for all patients.

How should Glycinorm-80 be stored and disposed of?

How to Store and Dispose of Glycinorm-80

The proper storage and disposal of Glycinorm-80 tablets are defined by regulatory authorities to ensure stability and safety. The medicine must be kept out of the sight and reach of children and stored in a cool and dry place.

Official Storage and Handling

Requirement Specific Condition
Temperature Store below 25 C or 30 C (check specific label).
Protection Protect from light and moisture; keep in the original container.

Disposal Instructions

Glycinorm-80 must not be used after the printed expiry date. To help protect the environment, unused or expired medicine must not be thrown away with household waste or disposed of in wastewater. Consult a pharmacist for instructions on how to properly discard the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Glycinorm-80 found in:

A-Z Index: